A significant portion of the global workforce operates under schedules that commence well before the typical dawn, with millions commencing their professional duties during the pre-sunrise hours. While overnight shifts often garner attention for their disruptive nature, the challenges faced by individuals engaged in early morning rotations are equally profound, frequently manifesting as debilitating fatigue. This pervasive somnolence, a hallmark of Shift Work Disorder (SWD), poses a substantial threat to cognitive function, diminishes operational efficacy, and compromises personal and public safety. In a pivotal development for this underserved demographic, a recent clinical investigation spearheaded by researchers affiliated with Mass General Brigham has illuminated the potential of solriamfetol, a wakefulness-promoting pharmaceutical agent, to enhance alertness among early morning shift workers. The outcomes of this groundbreaking study have been formally presented in the esteemed journal NEJM Evidence.
The absence of dedicated clinical trials investigating therapeutic interventions for SWD within the early morning shift worker population represented a considerable void in medical understanding, particularly given the prevalence of such schedules. "Until now, no clinical trial had tested a treatment for shift work disorder in early-morning shift workers, even though this is the most common type of shift schedule," stated Dr. Charles A. Czeisler, the senior author of the study and chief of the Division of Sleep and Circadian Medicine at Mass General Brigham. He further elaborated on the critical need this research addresses, noting, "This study addresses a major gap by focusing on the workers who start their day when most people are still asleep." This research aims to rectify that oversight by focusing on individuals who begin their workday when their circadian rhythms are biologically signaling for sleep.
The societal reliance on individuals who operate outside the conventional 9-to-5 paradigm is substantial, encompassing a diverse array of essential services. Approximately one-quarter of all workers engage in non-standard hours, a category that prominently includes those whose professional day begins in the very early morning. It is noteworthy that many individuals within this group do not self-identify as "shift workers," often perceiving their routine as merely an adjustment to an earlier start time rather than a deviation from typical sleep-wake cycles. Nevertheless, these individuals are demonstrably susceptible to the adverse effects of SWD, characterized by irregular sleep patterns and persistent daytime drowsiness that can significantly impair daily functioning.
The inherent conflict between early morning work schedules and the body’s natural biological inclination presents a formidable challenge. As Dr. Kirsi-Marja Zitting, the lead author and an investigator within the Division of Sleep and Circadian Medicine at Mass General Brigham, explained, "People who start work between 3 a.m. and 7 a.m. are waking up at a time when the brain is biologically programmed to sleep. That makes staying alert extraordinarily difficult, even when they are highly motivated." This biological discordance results in a dual burden for these workers: profound sleepiness during their work hours and difficulties achieving adequate restorative sleep during their limited off-duty periods. This persistent fatigue can significantly impact their ability to perform tasks, maintain focus, and engage in safe practices.
The ramifications of untreated Shift Work Disorder extend far beyond mere inconvenience, encompassing a spectrum of serious health and safety concerns. These include a measurable decline in cognitive acuity, leading to reduced mental sharpness and impaired problem-solving abilities. This diminished capacity can translate directly into decreased productivity in the workplace and an elevated risk of errors. Furthermore, the pervasive drowsiness associated with SWD significantly heightens the likelihood of motor vehicle accidents, both during the commute to and from work and potentially during work-related travel. Workplace injuries also become a more frequent occurrence as vigilance and reaction times are compromised. While pharmacological interventions such as modafinil have been employed to mitigate excessive sleepiness, their primary investigation and efficacy have largely been demonstrated in individuals working overnight shifts, and they may also present challenges in terms of disrupting subsequent sleep periods.
Solriamfetol, the pharmaceutical agent investigated in this novel trial, has previously garnered regulatory approval for the treatment of excessive sleepiness in individuals diagnosed with obstructive sleep apnea and narcolepsy. Its pharmacological profile suggested it as a promising candidate for SWD management due to its capacity to sustain wakefulness over extended durations without unduly interfering with the subsequent natural sleep cycle. This characteristic distinguishes it from some existing wakefulness-promoting medications that can have lingering effects.
The clinical trial designed to assess solriamfetol’s efficacy in early morning shift workers enrolled a cohort of 78 participants who had been diagnosed with SWD. The study employed a rigorous randomized, placebo-controlled design, wherein participants were assigned to receive either solriamfetol or a placebo on their scheduled workdays over a four-week intervention period. A critical component of the study involved objective assessments of participants’ ability to remain awake and alert within a controlled laboratory environment, simulating the low-stimulation conditions often encountered during early morning work hours, precisely timed to correspond with their typical work shifts. In parallel, participants provided subjective reports on their daily functioning and engaged in regular consultations with clinical researchers to monitor their progress and well-being.
The results following the four-week treatment period demonstrated a clear and statistically significant improvement in alertness and performance among participants who received solriamfetol. These individuals reported experiencing less daytime sleepiness and exhibited a demonstrably greater capacity to remain awake and engaged during the simulated work hours compared to the placebo group. Furthermore, both the participants themselves and the observing clinicians reported notable enhancements in overall daily functioning, a discernible improvement in work-related performance, and a heightened ability to successfully manage their routine daily responsibilities.
The magnitude of the observed improvements carried significant clinical weight, as highlighted by Dr. Czeisler. "The improvement we saw is clinically meaningful," he asserted, emphasizing the practical benefits. "These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life." He underscored the societal contribution of these essential workers and the often-unrecognized physiological toll they endure, adding, "Shift workers are essential to how our society functions, yet they often pay a hidden biological cost. This study shows we can do better for them."
Despite these encouraging findings, the researchers underscored the necessity for further investigation into the long-term implications of solriamfetol use in this population. The current study, while providing valuable initial insights, was of a relatively short duration (four weeks) and focused on otherwise healthy adults. Consequently, comprehensive understanding of sustained efficacy and potential cumulative effects will require additional research. The research team is actively pursuing these objectives and has initiated enrollment for a subsequent clinical trial designed to evaluate solriamfetol’s effects in individuals working overnight shifts. Successful outcomes from this future study could potentially support broader regulatory approval for solriamfetol’s use in managing Shift Work Disorder across a wider range of shift schedules.
The research team involved in this study comprised numerous Mass General Brigham authors, including Kirsi-Marja Zitting, Charles A. Czeisler, Katherine R. Gilmore, Brandon J. Lockyer, Wei Wang, Nicolas C. Issa, Stuart F. Quan, Jonathan S. Williams, and Jeanne F. Duffy. Eileen B. Leary also contributed as an additional author. Funding for this research was provided by Jazz Pharmaceuticals, Axsome Therapeutics, and the Brigham and Women’s Hospital Center for Clinical Investigation. The clinical trial was registered under the identifier NCT04788953.
About the Author
